Fresenius Medical Care AG & Co. KGaA — Cyborg Score 7/10
Strong
Healthcare Providers and Services - Dialysis and Renal Care
Strategic Profile
The company reported strong organic revenue growth of 10% in Q3 2025, with operating income growth accelerating to 28% and operating income margin expanding to 11.7%. The FME25+ transformation program is delivering sustainable cost savings, with EUR 174 million delivered in the first nine months of 2025 toward a full-year target of EUR 180 million, with cumulative savings expected to reach EUR 1,050 million by year-end 2027. The company has committed to returning excess capital to shareholders through an initial EUR 1 billion share buyback program commenced in August.
Cyborg Score Rationale
Strong double-digit organic revenue and operating income growth in recent quarters with margin expansion demonstrate operational momentum. The company's market capitalization of $13.15 billion reflects a significant but consolidating market. Challenges include US government shutdown and healthcare policy uncertainties.
Top Insights
Q3 2025 delivered 10% organic revenue growth with 28% operating income growth and expanding 11.7% operating margins
Company operates as the largest dialysis provider globally with significant market share in dialysis products
EUR 1 billion share buyback program underway with EUR 151 million invested as of September 30, 2025
High-volume HDF rollout progressing well with positive nephrologist feedback and expected to positively impact referrals and treatment growth in 2026
Named Competitors
DaVita — Major U.S. dialysis services and vascular care provider
Baxter — Global renal care and dialysis products manufacturer
B. Braun — Medical devices and infusion therapy provider
Outset Medical — Dialysis technology and consumables provider
Recent Developments
(January 2026) Charles Hugh-Jones appointed as Global Chief Medical Officer effective January 1, 2026
(November 2025) Q3 2025 results showed 10% organic revenue growth with 28% operating income growth
(September 2025) EUR 174 million of FME25+ savings delivered through nine months with continued momentum
(August 2025) Launched EUR 1 billion share buyback program with first tranche of up to EUR 600 million
Open the full interactive Fresenius Medical Care AG & Co. KGaA report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.